Von Willebrand disease

View All

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Patients with more severe forms of the disease can experience s...

Find More

von-willebrand-disease-vwd-market
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is one of these proteins (VWF). VWD patients have either a low level of VWF in their blood or the VWF protein does not functi...

Find More

bleeding-disorders-therapeutics-market-size-share-trends-growth-forecast
Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?

Bleeding disorders, also known as coagulopathy, are a group of conditions in which the blood cannot clot properly due to the missing or defective protein. Bleeding Disorder can affect a person irrespective of his genders, ages and race and the person is likely to bleed more than the average person. A minor cut or s...

Find More

Delveinsight
Global Hemophilia Market

Get Market Intelligence of Hemophilia Market with DelveInsight The Haemophilia Market is driven by clotting factor concentrates. Besides hemophilia A and B, and those with von Willebrand disease (VWD), is also sometimes treated with clotting factor. Currently about 20,000 people have hemophilia in the US; about ...

Find More